Chinese Japanese Germany Korea


Valrubicin structure
Chemical Name:
Molecular Formula:
Formula Weight:
MOL File:

Valrubicin Properties

Melting point:
116-117 °C
Boiling point:
135-136 C
1.3473 (estimate)
Water Solubility 
NCI Dictionary of Cancer Terms
AD 32; valrubicin; Valstar
  • Risk and Safety Statements
Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26-37/39
HS Code  2941906000
Toxicity dnd-hmn:lym 3 mg/L CJBIAE 58,720,80

Valrubicin price More Price(3)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 22964 Valrubicin ≥98% 56124-62-0 500μg $68 2020-06-24 Buy
Cayman Chemical 22964 Valrubicin ≥98% 56124-62-0 1mg $129 2020-06-24 Buy
Cayman Chemical 22964 Valrubicin ≥98% 56124-62-0 5mg $544 2020-06-24 Buy

Valrubicin Chemical Properties,Uses,Production


Valrubicin was launched as a new 'chemotherapeutic agent for the treatment of bladder cancer, particularly in patients with BCG-refractory carcinoma in situ (CIS) of the bladder for whom immediate cystectomy is unacceptable. It belongs to the class of anthracyclines, the widest used in human cancers, and is a N-trifluoroacetyl 14-valerate derivative of doxorubicin.Valrubicin can be obtained in 3 steps from daunomycin by N-trifluoroacetylation of the sugar moiety then iodination of the 2-acetyl group and introduction of a valerate residue. A proposed mechanism involved in the cytotoxicity of Valrubicin coud be the blockade of SV40 large T antigen helicase; this cellular enzyme is involved in the formation of a ternary complex with DNA to maintain the topographic structure of DNA during transcription. In patients with CIS of bladder refractory to front line and second line therapies, intravesical instillation of Valrubicin resulted in a complete response with a significant rate and allowed a delay in cystectomy. Systemic absorption was minimal and accordingly produced a lower incidence of cardiotoxicity compared with doxorubicin.

Chemical Properties

Red Solid


Anthra Pharm. (US)


Chemotherapy drug used to treat cancer of the bladder.

brand name

Valstar (Valera).

General Description

Valrubicin is available in 200-mg vials for intravesicular administrationin the treatment of bladder cancer (orphan drugstatus). The increased lipophilicity associated with the valericacid ester and trifluoro acetate functionalities increasestissue penetration and remains intact because, in large measure,of the lack of exposure to hydrolyzing enzymes causedby direct delivery into the bladder followed by voiding ofthe instilled solution. This local action also minimizes cardiotoxicityand other adverse effects seen with other anthracyclines.The major adverse effects that are seen are bladderirritation and reddening of the urine.

Clinical Use

Valrubicin currently has orphan drug status in the treatment of bacille Calmette-Guérin (BCG)–refractory bladder cancer (the total patient population is ~1,000 individuals) and is used with patients for whom surgical intervention would result in high morbidity or death.

Side effects

The most commonly reported adverse reactions are abdominal pain, urinary tract infection, hematuria, and dysuria. Systemic exposure to the drug and its metabolites would, of course, be greater in patients whose bladder wall integrity has been compromised by disease, and these patients should not receive valrubicin.

Safety Profile

Poison by intraperitoneal route.Human mutation data reported. When heated todecomposition it emits toxic fumes of Fí and NOx.


It is administered directly into the bladder through a catheter (intravesically). The lipophilic drug is water insoluble, but it dissolves in an aqueous vehicle that includes polyoxyethylene glycol and ethanol. The patient retains the drug in the bladder for 2 hours, then voids the solution in the normal fashion. Valrubicin is active as administered, and despite the fact that hydrolysis of the ester and trifluoroacetamide can be envisioned, it is excreted essentially unchanged. Less than 1% of an administered dose is absorbed systemically, so there is essentially no exposure to metabolizing enzymes. The reduced C13-alcoholic metabolite does not form to any appreciable extent during the 2-hour treatment period. Therapy is considered to be almost exclusively local, and there is little risk for cardiac toxicity, bone marrow suppression, drug–drug interactions, or other side effects.

Valrubicin Preparation Products And Raw materials

Raw materials

Preparation Products

Valrubicin Suppliers

Global( 122)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21837 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22625 55
career henan chemical co
+86-371-86658258 CHINA 30043 58
Shenzhen Nexconn Pharmatechs Ltd
15013857715 CHINA 3000 58
Chemwill Asia Co.,Ltd.
86-21-51861608;;; CHINA 23977 58
Hubei Jusheng Technology Co.,Ltd.
027-59599243 CHINA 28231 58
Xiamen AmoyChem Co., Ltd
+86 592-605 1114 CHINA 6371 58
18627774460 CHINA 743 58
Hubei xin bonus chemical co. LTD
027-59338440 CHINA 23045 58
BOC Sciences
1-631-614-7828 United States 20039 58

View Lastest Price from Valrubicin manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-08-27 Valrubicin
US $0.00-0.00 / KG 1g 99.0% 10kg/month Beijing Yibai Biotechnology Co., Ltd
2020-04-30 Valrubicin
US $0.00-0.00 / 公斤 1公斤 99.0% 800 ton Shaanxi Dideu Medichem Co. Ltd
2019-08-07 Valrubicin
US $3.00 / KG 1KG 99% 100kg career henan chemical co

56124-62-0(Valrubicin)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved